Aytu BioPharma, Inc.
Aytu BioPharma, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2014, the company has rapidly established itself in the development and commercialisation of innovative therapeutics, particularly in the fields of urology and men's health. Aytu's core products, including the well-regarded prescription medications and diagnostic solutions, are designed to address unmet medical needs, setting them apart in a competitive market. With a focus on enhancing patient outcomes, Aytu BioPharma has achieved significant milestones, including strategic partnerships and product launches that underscore its commitment to advancing healthcare. The company’s unique approach to drug development and its dedication to quality have positioned it as a notable entity within the biopharmaceutical landscape, making strides in improving the lives of patients across its operational regions.
DitchCarbon Score
How does Aytu BioPharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aytu BioPharma, Inc.'s score of 18 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aytu BioPharma, Inc.'s reported carbon emissions
Aytu BioPharma, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The company has not outlined any formal climate commitments or initiatives aimed at reducing carbon emissions. In the absence of specific data, it is unclear how Aytu BioPharma is addressing climate change or contributing to sustainability efforts within the biopharmaceutical industry.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aytu BioPharma, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
